Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication

被引：176

作者：

Korba, Brent E. ^{[1
]}

Montero, Abigail B. ^{[1
]}

Farrar, Kristine ^{[1
]}

Gaye, Karen ^{[1
]}

Mukerjee, Sampa ^{[1
]}

Ayers, Marc S. ^{[2
]}

Rossignol, Jean-Francois ^{[2
,3
]}

机构：

[1] Georgetown Univ, Med Ctr, Dept Microbiol & Immunol, Washington, DC 20007 USA

[2] Romarck Inst Med Res, Tampa, FL 33607 USA

[3] Stanford Univ, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA

来源：

ANTIVIRAL RESEARCH | 2008年 / 77卷 / 01期

关键词：

hepatitis B virus; hepatitis C virus; nitazoxanide; thiazolides; antiviral therapy;

D O I：

10.1016/j.antiviral.2007.08.005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Nitazoxanide (NTZ), a thiazolide anti-infective, is active against anaerobic bacteria, protozoa, and a range of viruses in cell culture models, and is currently in phase 11 clinical development for treating chronic hepatitis C. In this report, we characterize the activities of NTZ and its active metabolite, tizoxanide (TIZ), along with other thiazolides against hepatitis B virus (HBV) and hepatitis C virus (HCV) replication in standard antiviral assays. NTZ and TIZ exhibited potent inhibition of both HBV and HCV replication. NTZ was equally effective at inhibiting replication of lamivudine (LMV) and adefovir dipovoxil (ADV)-resistant HBV mutants and against T-C-methyl cytidine (2'CmeC) and telaprevir (VX-950)resistant HCV mutants. NTZ displayed synergistic interactions with LMV or ADV against HBV, and with recombinant interferon alpha-2b (IFN) or 2'CmeC against HCV. Pre-treatment of HCV replicon-containing cells with NTZ potentiated the effect of subsequent treatment with NTZ plus IFN, but not NTZ plus 2'CmeC. NTZ induced reductions in several HBV proteins (HBsAg, HBeAg, HBcAg) produced by 2.2.15 cells, but did not affect HBV RNA transcription, NTZ, TIZ, and other thiazolides are promising new antiviral agents that may enhance current or future anti-hepatitis therapies. (C) 2007 Published by Elsevier B.V.

引用

页码：56 / 63

页数：8

共 36 条

[1] Identification and characterization of mutations in hepatitis B virus resistant to lamivudine [J].

Allen, MI ;

Deslauriers, M ;

Andrews, CW ;

Tipples, GA ;

Walters, KA ;

Tyrrell, DLJ ;

Brown, N ;

Condreay, LD .

HEPATOLOGY, 1998, 27 (06) :1670-1677

[2] Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial [J].

Amadi, B ;

Mwiya, M ;

Musuku, J ;

Watuka, A ;

Sianongo, S ;

Ayoub, A ;

Kelly, P .

LANCET, 2002, 360 (9343) :1375-1380

[3] Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase [J].

Angus, P ;

Vaughan, R ;

Xiong, S ;

Yang, HL ;

Delaney, W ;

Gibbs, C ;

Brosgart, C ;

Colledge, D ;

Edwards, R ;

Ayres, A ;

Bartholomeusz, A ;

Locarnini, S .

GASTROENTEROLOGY, 2003, 125 (02) :292-297

[4] MULTIPLE-DRUG EFFECT ANALYSIS WITH CONFIDENCE-INTERVAL [J].

BELENKII, MS ;

SCHINAZI, RF .

ANTIVIRAL RESEARCH, 1994, 25 (01) :1-11

[5] Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture [J].

Blight, KJ ;

McKeating, JA ;

Marcotrigiano, J ;

Rice, CM .

JOURNAL OF VIROLOGY, 2003, 77 (05) :3181-3190

[6] Efficient initiation of HCV RNA replication in cell culture [J].

Blight, KJ ;

Kolykhalov, AA ;

Rice, CM .

SCIENCE, 2000, 290 (5498) :1972-1974

[7]

Broekhuysen J, 2000, INT J CLIN PHARM TH, V38, P387

[8]

Chen Stephen L, 2006, Int J Med Sci, V3, P47

[9]

Courcambeck J, 2006, ANTIVIR THER, V11, P847

[10] Nitazoxanide: A new thiazolide antiparasitic agent [J].

Fox, LM ;

Saravolatz, LD .

CLINICAL INFECTIOUS DISEASES, 2005, 40 (08) :1173-1180

← 1 2 3 4 →